dc.contributor.author | Hizal, M | |
dc.contributor.author | Bilgin, B | |
dc.contributor.author | Paksoy, N | |
dc.contributor.author | Acikgoz, O | |
dc.contributor.author | Sezer, A | |
dc.contributor.author | Gurbuz, M | |
dc.contributor.author | Ak, N | |
dc.contributor.author | Yucel, S | |
dc.contributor.author | Ayhan, M | |
dc.contributor.author | Erol, C | |
dc.contributor.author | Demirkiran, A | |
dc.contributor.author | Mandel, NM | |
dc.contributor.author | Shbair, A | |
dc.contributor.author | Gokmen, I | |
dc.contributor.author | Basoglu, T | |
dc.contributor.author | Paydas, S | |
dc.contributor.author | Demiray, AG | |
dc.contributor.author | Iriagac, Y | |
dc.contributor.author | Sakalar, T | |
dc.contributor.author | Zeynelgil, E | |
dc.contributor.author | Tatli, AM | |
dc.contributor.author | Bahceci, A | |
dc.contributor.author | Guven, DC | |
dc.contributor.author | Caner, B | |
dc.contributor.author | Can, A | |
dc.contributor.author | Gulmez, A | |
dc.contributor.author | Karakas, Y | |
dc.contributor.author | Yalcin, B | |
dc.contributor.author | Demirkazik, A | |
dc.contributor.author | Bilici, A | |
dc.contributor.author | Aydiner, A | |
dc.contributor.author | Yumuk, PF | |
dc.contributor.author | Sendur, MAN | |
dc.date.accessioned | 2022-10-11T12:55:24Z | |
dc.date.available | 2022-10-11T12:55:24Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://hdl.handle.net/11616/74849 | |
dc.description.abstract | Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. | |
dc.source | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | |
dc.title | The real-life efficacy and safety of osimertinib in pretreated advanced | |
dc.title | non-small cell lung cancer patients with T790M mutation: a Turkish | |
dc.title | Oncology Group Study |
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |